Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results – – Ended 2025 with ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
9hon MSN
Scientists report new immune insights and targets into LRRK2 mutations in Parkinson's disease
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder caused by the loss of ...
Engineers at the University of California have developed a new data structure and compression technique that enables the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback